AM-Pharma   Report issue

For profit Phase 2 Phase 3
Founded: Bunnik Utrecht Netherlands (2000)

Organization Overview

First Clinical Trial
2004
NCT00430859
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AM-Pharma | AM Pharma BV

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Bacteremia (Phase 2)

Bacterial Infections (Phase 2)

Candidemia (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Multiple Organ Failure (Phase 2)

Mycoses (Phase 2)

Sepsis (Phase 3)

Staphylococcal Infections (Phase 2)

Toxemia (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 6